Literature DB >> 30614663

Generation of a Core Set of Items to Develop Classification Criteria for Scleroderma Renal Crisis Using Consensus Methodology.

Emily-Ann Butler1, Murray Baron2, Agnes B Fogo3, Tracy Frech4, Cybele Ghossein5, Eric Hachulla6, Sabrina Hoa7, Sindhu R Johnson8, Dinesh Khanna9, Luc Mouthon10, Mandana Nikpour11, Susanna Proudman12, Virginia Steen13, Edward Stern14, John Varga5, Christopher Denton14, Marie Hudson15.   

Abstract

OBJECTIVE: To generate a core set of items to develop classification criteria for scleroderma renal crisis (SRC) using consensus methodology.
METHODS: An international, multidisciplinary panel of experts was invited to participate in a 3-round Delphi exercise developed using a survey based on items identified by a scoping review. In round 1, participants were asked to identify omissions and clarify ambiguities regarding the items in the survey. In round 2, participants were asked to rate the validity and feasibility of the items using Likert-type scales ranging from 1 to 9 (where 1 = very invalid/unfeasible, 5 = uncertain, and 9 = very valid/feasible). In round 3, participants reviewed the results and comments from round 2 and were asked to provide final ratings. Items rated as highly valid and feasible (median scores ≥7 for each) in round 3 were selected as the provisional core set of items. A consensus meeting using a nominal group technique was conducted to further reduce the core set of items.
RESULTS: Ninety-nine experts from 16 countries participated in the Delphi exercise. Of the 31 items in the survey, consensus was achieved on 13, in the categories hypertension, renal insufficiency, proteinuria, and hemolysis. Eleven experts took part in the nominal group technique discussion, where consensus was achieved in 5 domains: blood pressure, acute kidney injury, microangiopathic hemolytic anemia, target organ dysfunction, and renal histopathology.
CONCLUSION: A core set of items that characterize SRC was identified using consensus methodology. This core set will be used in future data-driven phases of this project to develop classification criteria for SRC.
© 2019, American College of Rheumatology.

Entities:  

Mesh:

Year:  2019        PMID: 30614663     DOI: 10.1002/art.40809

Source DB:  PubMed          Journal:  Arthritis Rheumatol        ISSN: 2326-5191            Impact factor:   10.995


  9 in total

1.  French recommendations for the management of systemic sclerosis.

Authors:  Eric Hachulla; Christian Agard; Yannick Allanore; Jerome Avouac; Brigitte Bader-Meunier; Alexandre Belot; Alice Berezne; Anne-Sophie Bouthors; Geraldine Condette-Wojtasik; Joël Constans; Pascal De Groote; Elisabeth Diot; Florence Dumas; Patrick Jego; Francisca Joly; David Launay; Veronique Le Guern; Janine-Sophie Le Quintrec; Geraldine Lescaille; Christophe Meune; Bruno Moulin; Christelle Nguyen; Nadine Omeish; Frederic Pene; Marie-Aleth Richard; Juliette Rochefort; Alexandra Roren; Olivier Sitbon; Vincent Sobanski; Marie-Elise Truchetet; Luc Mouthon
Journal:  Orphanet J Rare Dis       Date:  2021-07-26       Impact factor: 4.123

Review 2.  Renal Disease and Systemic Sclerosis: an Update on Scleroderma Renal Crisis.

Authors:  Alice Cole; Voon H Ong; Christopher P Denton
Journal:  Clin Rev Allergy Immunol       Date:  2022-06-01       Impact factor: 8.667

3.  Mortality and morbidity in scleroderma renal crisis: A systematic literature review.

Authors:  Hyein Kim; Frédéric Lefebvre; Sabrina Hoa; Marie Hudson
Journal:  J Scleroderma Relat Disord       Date:  2020-06-01

4.  Mammalian target of rapamycin is activated in the kidneys of patients with scleroderma renal crisis.

Authors:  Jessica Salituri; Natalie Patey; Tomoko Takano; Pierre Fiset; Sonia Del Rincon; Laeora Berkson; Murray Baron; Marie Hudson
Journal:  J Scleroderma Relat Disord       Date:  2019-11-13

5.  Zibotentan in systemic sclerosis-associated chronic kidney disease: a phase II randomised placebo-controlled trial.

Authors:  Edward P Stern; Lauren V Host; Ivy Wanjiku; K Jane Escott; Peter S Gilmour; Rachel Ochiel; Robert Unwin; Aine Burns; Voon H Ong; Helen Cadiou; Aidan G O'Keeffe; Christopher P Denton
Journal:  Arthritis Res Ther       Date:  2022-06-01       Impact factor: 5.606

6.  New risk model is able to identify patients with a low risk of progression in systemic sclerosis.

Authors:  Nina Marijn van Leeuwen; Marc Maurits; Sophie Liem; Jacopo Ciaffi; Nina Ajmone Marsan; Maarten Ninaber; Cornelia Allaart; Henrike Gillet van Dongen; Robbert Goekoop; Tom Huizinga; Rachel Knevel; Jeska De Vries-Bouwstra
Journal:  RMD Open       Date:  2021-05

7.  Acute Heart Failure in Scleroderma Renal Crisis: A Case Study for Review of Cardiac Disease in Systemic Sclerosis.

Authors:  Abhimanyu Amarnani; Perry Wengrofsky; Cindy L Tsui; Pramod Theetha Kariyanna; Naureen Kabani; Louis Salciccioli; Isabel M McFarlane
Journal:  Am J Med Case Rep       Date:  2019-11-05

8.  ACE inhibitors in SSc patients display a risk factor for scleroderma renal crisis-a EUSTAR analysis.

Authors:  Lukas Bütikofer; Pierre A Varisco; O Distler; O Kowal-Bielecka; Y Allanore; G Riemekasten; P M Villiger; S Adler
Journal:  Arthritis Res Ther       Date:  2020-03-24       Impact factor: 5.156

9.  Scleroderma renal crisis following mRNA vaccination against SARS-CoV-2.

Authors:  Julie Oniszczuk; Eléonore Pagot; Nicolas Limal; Sophie Hue; Vincent Audard; Anissa Moktefi; Khalil El Karoui
Journal:  Kidney Int       Date:  2021-07-30       Impact factor: 10.612

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.